Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 103 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibHughes, T.; Lipton, J.; Spector, N.; Cervantes, F.; Pasquini, R.; Clementino, N.; Dorlhiac Llacer, P.; Schwarer, A.; Mahon, F.; Rea, D.; Branford, S.; Purkayastha, D.; Collins, L.; Szczudlo, T.; Leber, B.
2013Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patientsRoss, D.; O'Hely, M.; Bartley, P.; Dang, P.; Score, J.; Goyne, J.; Sobrinho-Simoes, M.; Cross, N.; Melo, J.; Speed, T.; Hughes, T.; Morley, A.
2014Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinibOlshen, A.; Tang, M.; Cortes, J.; Gonen, M.; Hughes, T.; Branford, S.; Quintás-Cardama, A.; Michor, F.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2015Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemiaSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; Leclercq, T.; Hughes, T.; White, D.
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
2014The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmentBranford, S.; Yeung, D.; Ross, D.; Parker, W.; Braley, J.; Seymour, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2017Long-term outcomes of imatinib treatment for chronic myeloid leukemiaHochhaus, A.; Larson, R.; Guilhot, F.; Radich, J.; Branford, S.; Hughes, T.; Baccarani, M.; Deininger, M.; Cervantes, F.; Fujihara, S.; Ortmann, C.; Menssen, H.; Kantarjian, H.; O'Brien, S.; Druker, B.
2010Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scaleFletcher, L.; Prime, J.; Phillis, S.; Jamison, B.; Field, C.; Prime, H.; Sullivan, B.; Yeoman, A.; Georgievski, J.; Parker, W.; Slader, C.; Hughes, T.; Branford, S.; Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)